NCT05633277View on ClinicalTrials.gov

Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections

NAUnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

September 30, 2023

Study Completion Date

March 31, 2024

Conditions
Venous RefluxVenous InsufficiencyVenous UlcerVenous Disease
Interventions
PROCEDURE

Polidocanol

Sclerotherapy of the ulcer bed (polidocanol, sodium tetradecyl, etc) either in conjunction with a greater saphenous vein ablation treatment (RFA, EVLT, Venaseal, Varithena) at the same time or 3 months later.

Trial Locations (1)

43606

RECRUITING

Jobst Vascular Institute, ProMedica Toledo Hospital, Toledo

Sponsors

Collaborators (1)

Jobst Vascular Institute
All Listed Sponsors
collaborator

Jobst Vascular Institute

UNKNOWN

lead

ProMedica Health System

OTHER

NCT05633277 - Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections | Biotech Hunter | Biotech Hunter